(Q28370506)

English

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

0 references

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group (English)

0 references

Hepatitis B virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

N C Tassopoulos

1

0 references

R Volpes

2

0 references

G Pastore

3

0 references

J Heathcote

4

0 references

M Buti

5

0 references

R D Goldin

6

0 references

S Hawley

7

0 references

J Barber

8

0 references

L Condreay

9

0 references

D F Gray

10

0 references

language of work or name

0 references

publication date

March 1999

0 references

0 references

29

0 references

3

0 references

889-96

0 references

Seroconversion from Hepatitis B e Antigen to Antibody in Chronic Type B Hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural history and prognostic factors for chronic hepatitis type B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus carriers without precore mutations in hepatitis B e antigen-negative stage show more severe liver damage

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant: possible contribution of a single nucleotide in the precore region.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment and prevention of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy of hepatitis C: overview

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290321

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.510290321

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28370506&oldid=1980543583"